Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Denali Therapeutics ( (DNLI) ) has provided an announcement.
Denali Therapeutics has announced that its partner Sanofi has discontinued the Phase 2 study of oditrasertib for multiple sclerosis due to the drug failing to meet the primary and key secondary outcomes. This development may be of interest to those tracking the progress and potential impact of Denali’s pharmaceutical endeavors within the stock market.
See more insights into DNLI stock on TipRanks’ Stock Analysis page.
